116 related articles for article (PubMed ID: 23600404)
1. Editorial comment from Dr Chen to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Chen IJ
Int J Urol; 2013 Dec; 20(12):1227. PubMed ID: 23600404
[No Abstract] [Full Text] [Related]
2. Editorial comment from Dr Murtola to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Murtola TJ
Int J Urol; 2013 Dec; 20(12):1227-8. PubMed ID: 23600459
[No Abstract] [Full Text] [Related]
3. Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Yamada D; Nishimatsu H; Kumano S; Hirano Y; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Kume H; Homma Y
Int J Urol; 2013 Dec; 20(12):1220-7. PubMed ID: 23600973
[TBL] [Abstract][Full Text] [Related]
4. Drug Repositioning of the α
Florent R; Poulain L; N'Diaye M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32727149
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction.
Takeda M; Homma Y; Araki I; Kakizaki H; Yamanishi T; Yokota T; Gotoh M; Igawa Y; Seki N; Takei M; Yoshida M; Sugaya K; Nishizawa O;
BJU Int; 2011 Jul; 108(1):100-7. PubMed ID: 21062392
[TBL] [Abstract][Full Text] [Related]
6. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest.
Kanda H; Ishii K; Ogura Y; Imamura T; Kanai M; Arima K; Sugimura Y
Int J Cancer; 2008 Jan; 122(2):444-51. PubMed ID: 17918159
[TBL] [Abstract][Full Text] [Related]
7. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
[TBL] [Abstract][Full Text] [Related]
8. Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil.
Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
Radiat Oncol; 2014 Dec; 9():302. PubMed ID: 25544509
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
10. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
Hori Y; Ishii K; Kanda H; Iwamoto Y; Nishikawa K; Soga N; Kise H; Arima K; Sugimura Y
Cancer Prev Res (Phila); 2011 Jan; 4(1):87-96. PubMed ID: 21205739
[TBL] [Abstract][Full Text] [Related]
11. Editorial comment from Dr Funahashi to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Funahashi Y
Int J Urol; 2013 May; 20(5):521. PubMed ID: 23131001
[No Abstract] [Full Text] [Related]
12. Editorial comment from Dr Ishizuka to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Ishizuka O
Int J Urol; 2013 May; 20(5):520. PubMed ID: 23078593
[No Abstract] [Full Text] [Related]
13. Editorial comment from Dr Park to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Park WH
Int J Urol; 2013 May; 20(5):519-20. PubMed ID: 23078577
[No Abstract] [Full Text] [Related]
14. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical evaluation of naftopidil enantiomers: Rat functional assays in vitro and estrogen/androgen induced rat benign prostatic hyperplasia model in vivo.
Huang JJ; Cai Y; Yi YZ; Huang MY; Zhu L; He F; Liu XW; Huang BY; Yuan M
Eur J Pharmacol; 2016 Nov; 791():473-481. PubMed ID: 27615445
[TBL] [Abstract][Full Text] [Related]
16. α(1)-adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume.
Yokoyama O; Aoki Y; Tsujimura A; Takao T; Namiki M; Okuyama A
World J Urol; 2011 Apr; 29(2):233-8. PubMed ID: 20387069
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells.
Iwamoto Y; Ishii K; Kanda H; Kato M; Miki M; Kajiwara S; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2017 Jun; 143(6):933-939. PubMed ID: 28243746
[TBL] [Abstract][Full Text] [Related]
18. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
Harris AM; Warner BW; Wilson JM; Becker A; Rowland RG; Conner W; Lane M; Kimbler K; Durbin EB; Baron AT; Kyprianou N
J Urol; 2007 Nov; 178(5):2176-80. PubMed ID: 17870114
[TBL] [Abstract][Full Text] [Related]
19. Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of α1-adrenoceptor blocking.
Masachika E; Kanno T; Nakano T; Gotoh A; Nishizaki T
Anticancer Res; 2013 Mar; 33(3):887-94. PubMed ID: 23482758
[TBL] [Abstract][Full Text] [Related]
20. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]